Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106167 · ClinicalTrials.gov registry record
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
A clinical trial, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- 20
- Enrollment target
NCT04106167: Clinical Trial study, sponsored by Fate Therapeutics.
NCT04106167 is a clinical trial that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04106167 was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Primary Outcome
OS defined as the interval between the date of the first NK cell infusion and the date of death due to any cause
Interventions
- GENETIC Allogeneic natural killer (NK) cell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2023-08-11 |
Why NCT04106167 stopped before completion
NCT04106167 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic natural killer (NK) cell is the first listed.
NCT04106167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04106167 about?
NCT04106167 is a clinical study titled "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy". Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this stu...
What is the current status of trial NCT04106167?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2019-06-11. Estimated completion is 2023-08-11.
What interventions are being tested in trial NCT04106167?
The interventions under investigation include: Allogeneic natural killer (NK) cell (GENETIC).
Who is sponsoring clinical trial NCT04106167?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI